Nilotinib is an FDA approved drug used for the treatment of Philadelphia Chromosome Positive CML, which is a cancer of blood ...

The company has received final approval from the United States Food and Drug Administration (USFDA) for its New Drug ...

Cipla has received final US FDA approval for its Nilotinib Capsules (50 mg, 150 mg, 200 mg) for the treatment of Philadelphia ...

Mahindra Lifespace Developers Ltd., Bank of India, Rail Vikas Nigam Ltd., Container Corp. and Cipla Ltd. are some of the ...

So, within the generic companies, from the US point of view, Cipla delivered a very good set of results supported by the ...

Cipla's stock settled 2.2% higher at ₹1,427 on Tuesday on the National Stock Exchange. The company expects to launch its breast cancer drug Abraxane, which was originally slated for a rollout in ...

Company’s consolidated profit after tax for ... Shares traded at ₹358.05 on the NSE, down 2.09%. Cipla Ltd recorded its consolidated net profit for the quarter ended December 2024 at ...

U.S. President Donald Trump said on Tuesday he intends to impose a "25% or higher" levies on semiconductors and ...

That more than made up for a 1% drop in sales in North America, Cipla's second-biggest market, and helped the company's total revenue climb 7.1% to 70.73 billion rupees, surpassing market ...

As per the brokerage firm, Cipla’s Q3FY25 exceeded expectations, mostly driven by a healthier product mix and lower research and development spending. The company reported a 7.1% YoY revenue ...

Umang Vohra, the company's CEO, confirmed Abraxane's launch in the second half of FY26, which will be manufactured at Cipla’s Goa facility following its recent regulatory approval. Meanwhile ...